Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

Characterization of Serotonin Receptors in Pregnant Human Myometrium

Yolande Cordeaux, Dharmintra Pasupathy, Joanne Bacon, D. Stephen Charnock-Jones and Gordon C. S. Smith
Journal of Pharmacology and Experimental Therapeutics March 2009, 328 (3) 682-691; DOI: https://doi.org/10.1124/jpet.108.143040
Yolande Cordeaux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dharmintra Pasupathy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne Bacon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Stephen Charnock-Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon C. S. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The monoamine, 5-hydroxytryptamine (5-HT), stimulates contraction of human uterine smooth muscle (myometrium), but the receptor subtypes involved have not been characterized. We studied the effects of a range of 5-HT receptor subtype-selective agonists and antagonists in isolated strips of myometrium obtained at the time of caesarean section. The 5-HT1A receptor agonist, 8-hydroxy-2-dipropylaminotetralin, produced an increase in contractions that was highly variable, of low potency, and was not significantly inhibited by the 5-HT1A antagonist WAY100635 [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide]. The 5-HT2 receptor agonist, α-methyl-5-hydroxytryptamine (α-Me-5-HT), produced a strong, consistent, and concentration-dependent stimulation of contractions (pEC50 = 7.60 ± 0.10, n = 5). The 5-HT2A receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to α-Me-5-HT, with a pKB value consistent with its known affinity for the 5-HT2A receptor (pKB = 8.47 ± 0.16, n = 5), but it had no effect on the response to oxytocin. The 5-HT2B and 5-HT2C receptor agonists, BW723C86 [(α-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine)] and Ro-60-01-75 [(S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methyl-ethylamine fumarate], produced inconsistent responses at potencies that were lower than expected for activation of their cognate receptors. The response to α-Me-5-HT was unaffected by the 5-HT2B and 5-HT2C receptor antagonists, SB204741 [(N-(1-methyl-1H-indolyl-5-yl)-N-(3-methyl-5-isothiazolyl)urea)] and RS102221 [8-[5-(2,4-dimethoxy-5-(4-trifluoromethyl phenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione]. The 5-HT1B/1D receptor agonist, sumatriptan [1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide], the 5-HT4 agonist, cisapride [4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidyl]-2-methoxy-benzamide], and the 5-HT7 agonist, AS19 [(2S)-(+)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)tetralin], all had no effect on myometrial contractility. 5-HT2A receptor mRNA and immunoreactivity were identified using reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry. Specific binding of [3H]ketanserin was demonstrated. This study provides strong evidence for the expression of contractile 5-HT2A receptors in pregnant human myometrium, and this receptor is a potential target for novel uterotonic therapies.

Footnotes

  • This work was supported by the Evelyn Trust and by the National Institute for Health Research Cambridge Comprehensive Biomedical Research Centre.

  • doi:10.1124/jpet.108.143040.

  • ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; RT, reverse transcriptase; PCR, polymerase chain reaction; AUC, area(s) under the curve; ANOVA, analysis of variance; RIPA, radioimmunoprecipitation assay; TBST, Tris-buffered saline/Tween 20; HRP, horseradish peroxidase; ketanserin, 3-[2-[4-(4-fluoro benzoyl) piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; WAY100635, [O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; 8-OH-DPAT, 8-hydroxy-2-dipropylaminotetralin; AS19, (2S)-(+)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)tetralin; BW723C86, (α-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine); cisapride, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)-propyl]-3-methoxy-4-piperidyl]-2-methoxy-benzamide; Ro 60-0175, (S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methyl-ethylamine fumarate; RS102221, 8-[5-(2,4-dimethoxy-5-(4-trifluoromethyl phenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione; SB269970, (R)-3-(2-(2-(4-methyl-piperidin-1-yl)ethyl)-pyrrolidine-1-sulfonyl)phenol hydrochloride; SB204741, (N-(1-methyl-1H-indolyl-5-yl)-N-(3-methyl-5-isothiazolyl)urea); sumatriptan, 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; DMSO, dimethyl sulfoxide; α-Me-5-HT, α-methyl-5-hydroxytryptamine; Ro-60-01-75, (S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methyl-ethylamine fumarate.

    • Received July 3, 2008.
    • Accepted December 12, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 382 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 382, Issue 2
1 Aug 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Serotonin Receptors in Pregnant Human Myometrium
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

Characterization of Serotonin Receptors in Pregnant Human Myometrium

Yolande Cordeaux, Dharmintra Pasupathy, Joanne Bacon, D. Stephen Charnock-Jones and Gordon C. S. Smith
Journal of Pharmacology and Experimental Therapeutics March 1, 2009, 328 (3) 682-691; DOI: https://doi.org/10.1124/jpet.108.143040

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCELLULAR AND MOLECULAR

Characterization of Serotonin Receptors in Pregnant Human Myometrium

Yolande Cordeaux, Dharmintra Pasupathy, Joanne Bacon, D. Stephen Charnock-Jones and Gordon C. S. Smith
Journal of Pharmacology and Experimental Therapeutics March 1, 2009, 328 (3) 682-691; DOI: https://doi.org/10.1124/jpet.108.143040
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CsA Downregulates Selenop Expression via a STAT3-FoxO1 Axis
  • Anisodamine Ameliorates Acute Lung Injury
  • ACE2 Inhibits LPS-Caused Lung Fibrosis
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics